Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Speciality Medicines IPO
Price Band
₹117.0–124.0
Issue Size
₹29.14 Cr
Lot Size
1,000 shares
Min Investment
₹248,000
2 LOTS MIN
GMP
—
Issue Price
₹124.0
Speciality Medicines IPO AI Summary
- Speciality Medicines IPO is listed on BSE SME in the Pharmaceuticals sector.
- Price band: ₹117.0–₹124.0 per share, lot size 1,000 shares (min. investment ₹248,000, 2 lots minimum).
- Subscription window: 20 Mar–24 Mar 2026, listing on 30 Mar 2026.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Speciality Medicines IPO Grey Market Premium (GMP) Today
GMP not available yet
Grey Market Premium is updated daily. Check back closer to the listing date.
About the Company
Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals — including high-cost oral and injectable medications used to treat complex chronic conditions — across both domestic and international markets. The company’s portfolio includes a wide range of speciality pharmaceutical finished formulations such as capsules, creams, eye drops, gels, infusions, inhalations and inhalers, injections, nasal sprays, ointments, ophthalmic solutions, oral solutions, oral suspensions, sachets, suspensions, and tablets. Through wide-ranging distribution channels, the company has built a trusted reputation with clients across more than 20 states in India and over 35 countries worldwide. Speciality Medicines Limited offers over 650 products (as of July 31, 2024) under the unregistered category, with a particular focus on therapeutic areas like: Oncology Immunology Neurology Rare Diseases Additionally, the company’s product range includes human and animal medicines, vaccines, and plasma products — all sourced from manufacturers that comply with global quality standards like EUGMP and PICS. Global Expansion and Registrations As of July 31, 2024, Speciality Medicines Limited has: 1 plasma product registered in Bolivia 127 products under registration across 8 countries As of July 31, 2024, Speciality Medicines Limited employs a team of 20 permanent employees across various departments, contributing to the company’s smooth and efficient operations.
Company Financials (₹ Cr)
As of 2025-10-31
| Period Ended | 31 Oct 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 45.57 | 39.98 | 22.68 |
| Total Income | 36.93 | 58.54 | 27.66 |
| Profit After Tax | 6.06 | 8.61 | 2.93 |
| EBITDA | 6.51 | 9.09 | 5.26 |
| NET Worth | 36.47 | 30.42 | 15.06 |
| Reserves and Surplus | 30.04 | 23.98 | 9.95 |
| Total Borrowing | 4.81 | 5.05 | 2.86 |
Key Ratios
EPS
₹13.38
NAV
₹47.26
ROE
37.85%
ROCE
33.39%
RoNW
28.30%
P/B Value
2.62
P/E Ratio
9.27
Market Cap
₹108.94 Cr
PAT Margin
14.77%
Debt/Equity
0.17
Promoters
Parth B Goyani and Goyani Sumit Babubhai
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Setting up of Research and Development (R&D) Centre at Revenue City Survey No. RV1/NA/61/1/50, Moje, Manda, Tal. Umargam, Dist. Valsad, Gujarat 12.68 2 Product Registration in International Markets and Product Development for sale in international markets 2.99 3 Funding for Marketing and Promotional Activities 1.66 4 To Meet Working Capital Requirements 8.00 5 General Corporate Purposes 0.25 6 Issue Expenses 3.57 Total 29.14
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total income was ₹27.66 Cr in the year ending 31 Mar 2024, rising to ₹58.54 Cr by 31 Mar 2025. However, it decreased to ₹36.93 Cr by 31 Oct 2025, though this is a 6-month figure, not a full year, so isn't directly comparable.
Profit Trend
Profit After Tax was ₹2.93 Cr in the year ending 31 Mar 2024, increasing to ₹8.61 Cr by 31 Mar 2025. It then fell to ₹6.06 Cr by 31 Oct 2025, though this is a 6-month figure, not a full year, so isn't directly comparable.
Grey Market Premium, Explained
The Grey Market Premium (GMP) refers to the unofficial trading of shares before they are listed on the stock exchange. It indicates the expected listing price of the IPO based on demand and supply dynamics in the grey market. A higher GMP suggests strong demand, while a lower or negative GMP indicates weaker demand.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their investment strategy, risk tolerance, and market conditions. It's essential to consider the company's growth potential and market position.
Who May Want to Wait
Investors who prefer stable returns and are risk-averse may want to avoid IPOs like this, as they can be subject to high volatility and uncertainty, particularly in the early stages of trading.
IPO Timeline, Explained
The IPO process includes several key dates: the issue opens on March 20, 2026, and closes on March 24, 2026. Allotment of shares will take place on March 25, 2026, and the listing date is set for March 30, 2026.
Listing Gains — The Risk
Listing gains refer to the potential profit an investor can make when shares of a company are listed on the stock exchange. However, these gains are not guaranteed and can be influenced by market conditions, investor sentiment, and the company's performance post-listing. Investors should be aware that the stock price may fluctuate significantly on the listing day.
This evaluation is generated from Speciality Medicines's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is the price band of Speciality Medicines IPO?
The price band of Speciality Medicines IPO is ₹117.0–₹124.0 per share.
When does Speciality Medicines IPO open and close?
Speciality Medicines IPO opens on 20 March 2026 and closes on 24 March 2026.
When does Speciality Medicines IPO list on the stock exchange?
Speciality Medicines IPO listed on 30 March 2026 at ₹124.0.
What is the lot size for Speciality Medicines IPO?
The lot size for Speciality Medicines IPO is 1000 shares, requiring a minimum investment of ₹248,000 (2 lots).
What is the lot size for this IPO?
The lot size for this IPO is 1000 shares.
What is the minimum investment required?
The minimum investment required is ₹248,000.
What is the price band for the IPO?
The price band for the IPO is ₹117.0 to ₹124.0.
When is the listing date for the IPO?
The listing date for the IPO is March 30, 2026.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected listing price of the IPO based on demand and supply in the unofficial market.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
20 Mar 2026
Close
24 Mar 2026
Allotment
25 Mar 2026
Listing
30 Mar 2026
Similar IPOs in Pharmaceuticals
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Speciality Medicines?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.